| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
a Beth Israel Medical Center, New York, New York; b Ortho Biotech Inc., Raritan, New Jersey, USA
Correspondence: Russell K. Portenoy, M.D., Department of Pain Medicine and Palliative Care, Beth Israel Medical Center, New York, New York 10003, USA. Telephone: 212-844-1505; Fax: 212-844-1503; e-mail: RPortenoy{at}BethIsraelNY.org
Fatigue is a highly prevalent condition among cancer patients. Although most cancer patients report that fatigue is a major obstacle to maintaining normal daily activities and quality of life, it is seldom assessed and treated in clinical practice. Few studies have explored its epidemiology, possible etiologies, or management. Cancer-related fatigue, which recently was accepted as a diagnosis in the International Classification of Diseases 10th Revision-Clinical Modification, reduces physical, psychological, and social functioning and results in significant distress for patients and caregivers. Adequate evaluation of fatigue must do more than simply assess severity. The assessment should clarify other characteristics, determine the degree to which fatigue interferes with the activities of daily living, and identify potential causes, including the underlying disease, disease treatments, intercurrent systemic disorders, psychological disorders, and other conditions. Possible primary therapies include modification of the patient's drug regimen, correction of metabolic abnormalities, and pharmacologic treatments for anemia (e.g., epoetin alfa), depression, or insomnia. Other symptomatic interventions include specific drug treatments, exercise, modification of activity and rest patterns, cognitive therapies, sleep hygiene approaches, and nutritional support. Pharmacologic approaches, which are supported by limited studies and growing clinical experience, include psychostimulant drugs, corticosteroids, and possibly other therapies. Although additional research is needed to further identify the causes and corresponding treatment of fatigue, practitioners should routinely assess and treat patients who may benefit from currently identified interventions, because fatigue can profoundly undermine the quality of life of patients with cancer.
This article has been cited by other articles:
 |
|
 |
|
  L. Radbruch, F. Strasser, F. Elsner, J. F. Goncalves, J. Loge, S. Kaasa, F. Nauck, P. Stone, and the Research Steering Committee of the European As Fatigue in palliative care patients -- an EAPC approach Palliative Medicine, January 1, 2008; 22(1): 13 - 32. [Abstract] [PDF]
|
|
|
|
 |
|
 J. K. Carroll, S. Kohli, K. M. Mustian, J. A. Roscoe, and G. R. Morrow Pharmacologic Treatment of Cancer-Related Fatigue Oncologist, May 1, 2007; 12(suppl_1): 43 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Mustian, G. R. Morrow, J. K. Carroll, C. D. Figueroa-Moseley, P. Jean-Pierre, and G. C. Williams Integrative Nonpharmacologic Behavioral Interventions for the Management of Cancer-Related Fatigue Oncologist, May 1, 2007; 12(suppl_1): 52 - 67. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-C. Shun, S. L. Beck, M. A. Pett, and S. J. Richardson Assessing Responsiveness of Cancer-Related Fatigue Instruments: Distribution-Based and Individual Anchor-Based Methods Oncologist, April 1, 2007; 12(4): 495 - 504. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Yennurajalingam and E. Bruera Palliative Management of Fatigue at the Close of Life: "It Feels Like My Body Is Just Worn Out" JAMA, January 17, 2007; 297(3): 295 - 304. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Barrett-Lee, C. Bokemeyer, P. Gascon, J.W.R. Nortier, M. Schneider, D. Schrijvers, S. Van Belle, and for the Ecas Advisory Board and Participating Cent Management of Cancer-Related Anemia in Patients with Breast or Gynecologic Cancer: New Insights Based on Results from the European Cancer Anemia Survey Oncologist, October 1, 2005; 10(9): 743 - 757. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Yates, S. Aranda, M. Hargraves, B. Mirolo, A. Clavarino, S. McLachlan, and H. Skerman Randomized Controlled Trial of an Educational Intervention for Managing Fatigue in Women Receiving Adjuvant Chemotherapy for Early-Stage Breast Cancer J. Clin. Oncol., September 1, 2005; 23(25): 6027 - 6036. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Rao and H. J. Cohen Symptom Management in the Elderly Cancer Patient: Fatigue, Pain, and Depression J Natl Cancer Inst Monographs, July 1, 2004; 2004(32): 150 - 157. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Iop, A. M. Manfredi, and S. Bonura Fatigue in cancer patients receiving chemotherapy: an analysis of published studies Ann. Onc., May 1, 2004; 15(5): 712 - 720. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Dillon and J. Kelly The Status of Cancer Fatigue on the Island of Ireland: AIFC Professional and Interim Patient Surveys Oncologist, February 1, 2003; 8(90001): 22 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Bodurka, C. Levenback, J. K. Wolf, J. Gano, J. T. Wharton, J. J. Kavanagh, and D. M. Gershenson Phase II Trial of Irinotecan in Patients With Metastatic Epithelial Ovarian Cancer or Peritoneal Cancer J. Clin. Oncol., January 15, 2003; 21(2): 291 - 297. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Kirkwood, C. Bender, S. Agarwala, A. Tarhini, J. Shipe-Spotloe, B. Smelko, S. Donnelly, and L. Stover Mechanisms and Management of Toxicities Associated With High-Dose Interferon Alfa-2b Therapy J. Clin. Oncol., September 1, 2002; 20(17): 3703 - 3718. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Holzner, G. Kemmler, R. Greil, M. Kopp, A. Zeimet, M. Raderer, M. Hejna, S. Zochbauer, G. Krajnik, H. Huber, et al. The impact of hemoglobin levels on fatigue and quality of life in cancer patients Ann. Onc., June 1, 2002; 13(6): 965 - 973. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Glaspy, L. Degos, M. Dicato, and G. D. Demetri Comparable Efficacy of Epoetin Alfa for Anemic Cancer Patients Receiving Platinum- and Nonplatinum-Based Chemotherapy: A Retrospective Subanalysis of Two Large, Community-Based Trials Oncologist, April 1, 2002; 7(2): 126 - 135. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. S. Wang, S. A. Giralt, T. R. Mendoza, M. C. Engstrom, B. A. Johnson, N. Peterson, L. D. Broemeling, and C. S. Cleeland Clinical Factors Associated With Cancer-Related Fatigue in Patients Being Treated for Leukemia and Non-Hodgkin's Lymphoma J. Clin. Oncol., March 1, 2002; 20(5): 1319 - 1328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Quirt, C. Robeson, C. Y. Lau, M. Kovacs, S. Burdette-Radoux, S. Dolan, S. C. Tang, M. McKenzie, and F. Couture Epoetin Alfa Therapy Increases Hemoglobin Levels and Improves Quality of Life in Patients With Cancer-Related Anemia Who Are Not Receiving Chemotherapy and Patients With Anemia Who Are Receiving Chemotherapy J. Clin. Oncol., November 1, 2001; 19(21): 4126 - 4134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Cox and M. Pappagallo Modafinil: A gift to portmanteau American Journal of Hospice and Palliative Medicine, November 1, 2001; 18(6): 408 - 410. [Abstract] [PDF]
|
|
|
|
 |
|
 G. A Curt Fatigue in cancer BMJ, June 30, 2001; 322(7302): 1560 - 1560. [Full Text]
|
|
|
|
|
|
J. Savard and C. M. Morin Insomnia in the Context of Cancer: A Review of a Neglected Problem J. Clin. Oncol., February 1, 2001; 19(3): 895 - 908. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K. Portenoy Cancer-Related Fatigue: An Immense Problem Oncologist, October 1, 2000; 5(5): 350 - 352. [Full Text]
|
|
|
|
|
|
G. A. Curt, W. Breitbart, D. Cella, J. E. Groopman, S. J. Horning, L. M. Itri, D. H. Johnson, C. Miaskowski, S. L. Scherr, R. K. Portenoy, et al. Impact of Cancer-Related Fatigue on the Lives of Patients: New Findings From the Fatigue Coalition Oncologist, October 1, 2000; 5(5): 353 - 360. [Abstract] [Full Text]
|
|
|
|
|
|
G. A. Curt The Impact of Fatigue on Patients with Cancer: Overview of FATIGUE 1 and 2 Oncologist, June 1, 2000; 5(2008): 9 - 12. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| THE ONCOLOGIST | STEM CELLS | CME | ALPHAMED PRESS JOURNALS |
